<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Reth, M.</title>
    <link>http://repub.eur.nl/res/aut/2149/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/8407/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Expression of the pre-B cell receptor (pre-BCR) leads to activation of the
      adaptor molecule SLP-65 and the cytoplasmic kinase Btk. Mice deficient for
      one of these signaling proteins have an incomplete block in B cell
      development at the stage of large cycling pre-BCR+CD43+ pre-B cells. Our
      recent findings of defective SLP-65 expression in approximately 50% of
      childhood pre-B acute lymphoblastic leukemias and spontaneous pre-B cell
      lymphoma development in SLP-65-/- mice demonstrate that SLP-65 acts as a
      tumor suppressor. To investigate cooperation between Btk and SLP-65, we
      characterized the pre-B cell compartment in single and double mutant mice,
      and found that the two proteins have a synergistic role in the
      developmental progression of large cycling into small resting pre-B cells.
      We show that Btk/SLP-65 double mutant mice have a dramatically increased
      pre-B cell tumor incidence ( approximately 75% at 16 wk of age), as
      compared with SLP-65 single deficient mice (&lt;10%). These findings
      demonstrate that Btk cooperates with SLP-65 as a tumor suppressor in pre-B
      cells. Furthermore, transgenic low-level expression of a constitutive
      active form of Btk, the E41K-Y223F mutant, prevented tumor formation in
      Btk/SLP-65 double mutant mice, indicating that constitutive active Btk can
      substitute for SLP-65 as a tumor suppressor.</description>
    </item>
  </channel>
</rss>